Open AccessTime‐to‐reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease
Author(s) -
Haisma SjoukjeMarije,
Verkade Henkjan J.,
Scheenstra Rene,
Doef Hubert P.J.,
Bodewes Frank A.J.A.,
Rheenen Patrick F.
Publication year - 2019
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002458
Subject(s) - calprotectin , medicine , faecal calprotectin , gastroenterology , inflammatory bowel disease , ulcerative colitis , colitis , disease , immunology
ABSTRACT Objectives: Treatment targets in inflammatory bowel disease (IBD) move away from controlling symptoms towards complete recovery of the intestinal mucosa. Currently, the most frequently used noninvasive surrogate marker of mucosal healing is a faecal calprotectin concentration in the target range. This study tested if there was a relation between time‐to‐reach target calprotectin and first flare. Methods: We prospectively included new‐onset IBD patients ages 17 and younger in a cloud‐based registry (FastForwardCare) and followed them for at least 52 weeks. They were treated according to Dutch national guidelines that advocate a step‐up approach. Time‐to‐reach target was defined as the first calprotectin measurement below 250 μg/g after the start of induction therapy. Time‐to‐first flare was the time from the first calprotectin measurement below 250 μg/g until reappearance of symptoms with calprotectin values above 250 μg/g. Results: We included 76 patients (luminal Crohn disease [CD] 43); ulcerative colitis [UC] 33). Median age at diagnosis was, respectively 14.5 and 14.1 years. Median time‐to‐reach target calprotectin was 37 weeks in CD and 11 weeks in UC patients (Log‐rank test, P = 0.001). Once the calprotectin target was reached, time‐to‐first flare was significantly longer in CD than in UC patients (Log‐rank test, P = 0.001). CD patients with time‐to‐reach target calprotectin ≤12 weeks after conventional induction therapy (ie, exclusive enteral nutrition or steroids) had a more favorable disease course in the first year than those with time‐to‐reach target calprotectin >12 weeks (Log‐rank test, P = 0.057). In UC patients, time‐to‐reach target calprotectin ≤12 weeks is not associated with a favorable disease course in the first year. Conclusions: The findings of this prospective registry suggest that a quick response to conventional therapy predicts a favorable disease course in new‐onset paediatric CD, but not in UC. The concept “time‐to‐reach target calprotectin level” rationalizes the indefinite term “response to treatment” and is well suited for studying treatment effectiveness in real‐world practices.